What do systematic reviews say?

tDCS plus speech and language therapy (SLT) vs sham tDCS plus SLT

• Transcranial direct current stimulation (tDCS) for improving aphasia in adults with aphasia after stroke 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 112 participants
  Low
• Transcranial direct current stimulation (tDCS) for improving aphasia in adults with aphasia after stroke 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 80 participants
  Very low

tDCS plus speech and language therapy (SLT) vs sham tDCS plus SLT

• Transcranial direct current stimulation (tDCS) for improving aphasia in adults with aphasia after stroke 2019 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 298 participants
  Moderate
• Transcranial direct current stimulation (tDCS) for improving aphasia in adults with aphasia after stroke 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 80 participants
  Low

tDCS plus speech and language therapy (SLT) vs sham tDCS plus SLT

• Transcranial direct current stimulation (tDCS) for improving aphasia in adults with aphasia after stroke 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 21 participants
  Very low

Summary of findings 1: PLD with chemotherapy vs PLD alone

Summary of findings 3: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with PLD alone (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.92 [0.7, 1.21]
  1 study · 242 participants
  Moderate

Summary of findings 1: PLD with chemotherapy vs PLD alone

Summary of findings 3: PLD with chemotherapy showed no clear difference in progression‐free survival (PFS) compared with PLD alone (low certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.94 [0.73, 1.22]
  2 studies · 353 participants
  Low

Summary of findings 1: PLD with chemotherapy vs PLD alone

The review found no eligible studies for this question.

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings 1: PLD with chemotherapy vs PLD alone

Summary of findings 3: PLD with chemotherapy probably leads to higher overall severe adverse events (grade ≥ 3) compared with PLD alone (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  RR 2.48 [1.98, 3.09]
  1 study · 663 participants
  Moderate

Summary of findings 1: PLD with chemotherapy vs PLD alone

Summary of findings 3: PLD with chemotherapy probably leads to higher anaemia (grade ≥ 3) compared with PLD alone (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  RR 2.38 [1.46, 3.87]
  2 studies · 785 participants
  Moderate

Summary of findings 1: PLD with chemotherapy vs PLD alone

Summary of findings 3: PLD with chemotherapy probably leads to lower hand‐foot syndrome (grade ≥ 3) compared with PLD alone (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  RR 0.24 [0.14, 0.4]
  2 studies · 785 participants
  Moderate

Summary of findings 1: PLD with chemotherapy vs PLD alone

Summary of findings 3: PLD with chemotherapy showed no clear difference in neurological (grade ≥ 3) compared with PLD alone (low certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  RR 1.4 [0.85, 2.31]
  1 study · 663 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 183 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 147 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 208 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1250 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in change in grip strength from baseline to end of intervention compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 1.08 [0.37, 3.17]
  1 study · 137 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 344 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in effect on discontinuation of aromatase inhibitors (AI) compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 0.16 [0.01, 2.99]
  1 study · 147 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 44 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

It is very uncertain whether summary of findings table ‐ Systemic therapy changes incidence of AIMSS compared with control (very low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 0.82 [0.63, 1.06]
  2 studies · 240 participants
  Very low